Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Short Communication Volume 3 Issue 10

Gastrointestinal and Liver Disorders Encountered during the Covid-19-Pandemic-Strategies to Overcome and Nutritional Input to Boost Immunity

Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3

1Scientific Director, DR Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
2Scientific Director, Rotunda-A Centre for Human Reproduction, Mumbai, India
3Consultant Neurologist, Swami Satyanand Hospital, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, DR Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.

Received: July 25, 2020; Published: September 16, 2020


  We had reviewed on various aspects of COVID-19-disease from structure, presentation management, pregnancy and lactation, management of severe COVID-19-disease and effects on reproductive system [1-5]. Here we have emphasized on the GIT involvement aspect, besides liver and implications on endoscopy practice worldwide in, COVID-19 era. Digestive symptoms including anorexia, nausea, vomiting, diarrhea (N, V, D) - frequently reported in patients with COVID-19-disease [CD]. SARS-CoV-2 RNA was first detected in stool of the 1st reported CD-19 case in the USA, who also presented with the digestive symptoms of (N, V, D). In the biggest cohort-1099 patients with laboratory-confirmed CD-19 from 552 hospitals in China in January 2020, N, V, D were reported in 55 (5%) and 42 (3.8%) patients, respectively. Of the 204 patients with CD-19 and full investigations, 99 (48.5%) presented with digestive symptoms as main complaint. Patients with digestive symptoms had separate manifestations, like anorexia (83.8%), V, D and abdominal pain (0.4%). Digestive symptoms - might be presenting prior to respiratory symptoms, or only symptoms of CD-19. The mode for GIT infection of SARS-CoV is ACE2 cell receptor. SARS-CoV-2, having genome sequence of SARS-CoV (82%), might use the same ACE2, strain -SARS-CoV (2003). Xiao., et al. showed on endoscopic biopsy samples that ACE2 was rarely expressed in esophageal epithelium, but abundantly distributed in cilia of glandular epithelia, while staining of viral nucleocapsid protein was visualized in the cytoplasm of gastric, duodenal and rectum glandular epithelial cell, but not in esophageal epithelium. As found in another study in the small intestine, the crosstalk among SARS-CoV-2-ACE2 might disrupt the function of ACE2 and cause diarrhea. Chances of fecal-oral transmission of SARS-CoV-2 stressed on proper hand hygiene, stools handling and hospital sewage carefully in pts. SARS-CoV-2 in the GIT, signifies CD-19 infection in patients with preexisting digestive diseases and fecal microbiota transplant donors. To prevent SARS-CoV-2 transmission by fecal microbiota transplantation, more testing needed over current ones. GIT endoscopy departments face marked transmissions risk of virus during endoscopy. Earliest reports of CD-19, 40/138 showed high risk of infection for healthcare workers of infection. Possible routes of viral transmission on endoscopy examination - person-to-person, respiratory droplets, aerosols formed on endoscopy and contact with contaminated surroundings, body fluids and fecal material. Recommendation used-World Endoscopy Organization, ASGE, ESGE on endoscopy during the pandemic. Liver damage was common in the patients infected by the other 2 highly pathogenic coronavirus-SARS-CoV, MERS CoV associated with the severity of diseases. In patients with CD-19, several studies have documented the incidence of liver injury, indicating that 2 - 11% of patients with CD-19 had liver comorbidities and 16 - 53% cases reported abnormal levels of SGOT/PT. Guan., et al. and Huang showed that elevated AST levels were observed more in pts with severe disease. Liver injury might be due to viral infection in liver cells or due to other causes such as drug induced liver injury and systemic inflammation induced by CKS or pneumonia-related hypoxia. SARS virus has been shown to be present in the liver tissue, although the viral titer was relatively low because viral inclusions were not observed. The impact of COVID-19 in patients with preexisting chronic liver diseases, needs evaluation. From Chinese study showed that chronic hepatitis B infection pts didn’t have higher disease severity vs population as did world cases. Major changes to the standard management of GIT diseases, priorities like minimizing viral transmission, preserving PPE and freeing hospital beds have driven unconventional approaches to managing GI patients. Conversion of endoscopy units to CD units and redeployment of GI fellows and faculty has profoundly changed most GI services. Meanwhile, consult and procedural volumes have reduced drastically [7]. Sethi., et al. [8] showed how dealing specific consults and conditions has changed, the main focus is on noninvasive measures and maximizing medical therapies. Endoscopic procedures have been reserved for those timely interventions that are most likely to be therapeutic. The role of multidisciplinary discussion, although important, has become critical now. Advancing a clear vision and a transparent process for how to organize and triage care in the recovery phase will allow for a smooth transition to our new normal [8]. For percutaneous endoscopic gastrostomy (PEG) placements even in this time of pandemic needs to be avoided. Despite the viral effects of the SARS-CoV-2 in the GIT, enteral nutrition is still the preferred method of nutrition therapy for patients with CD-19 because of its multiple benefits in the gut. It supports the structural and functional integrity of the gut, thereby modulating systemic immunity, attenuating disease severity, aiding in good results. However, the presence of GI symptoms such as anorexia, N, V, D in some patients with CD-19 complicates this challenge to feed the patient [9].



  1. Kulvinder Kochar Kaur., et al. “A Comprehensive review on epidemiology, aetiopathogenesis, diagnosis and treatment of the novel corona virus syndrome –COVID-19”. Iberoamerican Journal of Medicine 2 (2020): 110-123.
  2. Kulvinder Kochar Kaur. “Editorial –Maximum possible efforts by which we will win over this Deadly Pandemic of COVID-19”. Acta Scientific Microbiology6 (2020): 01-03.
  3. Kulvinder Kochar Kaur., et al. “An Update on COVID19 from Etiopathogenesis, to role in male infertility”. Pregnancy Lactation, and Regarding treatment (2020).
  4. Kulvinder Kochar Kaur., et al. “Editorial-An update on management of severe COVID19presenting with Cytokine Release Syndrome responsible for most mortalities in COVID19”. Acta Scientific Microbiology8 (2020): 01-06.
  5. Kulvinder Kochar Kaur., et al. “An update on the place of ART with SARS CoV2-around and influence on Both Reproduction, transmission possibilities to, Progeny, Partners and Staff –What is the Answer”. Under review with Longdom Publishers.
  6. Kim Cho. “SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-AcetylSialylation in Virus–Host Interaction”. International Journal of Molecular Sciences 12 (2020): 4549.
  7. Aguila EJT., et al. “COVID-19 and its effects on the digestive system and endoscopy practice”. Journal of Gastroenterology and Hepatology 4 (2020) 324-331.
  8. Sethi A., et al. “Donning a New Approach to the Practice of Gastroenterology: Perspectives From the COVID-19 Pandemic Epicenter”. Clinical Gastroenterology and Hepatology 18 (2020): 1673-1681.
  9. Aguila EJT., et al. “Follow Your Gut: Challenges in Nutritional Therapy During the COVID-19 Pandemic”. Clinical Gastroenterology and Hepatology (2020).
  10. Soetikno R., et al. “Considerations in performing endoscopy during the COVID-19 pandemic”. Gastrointestinal Endoscopy1 (2020): 176-183.
  11. Montorfano L., et al. “Colorectal surgery obesity-related morbidity during COVID-19. Surgery for Obesity and Related Diseases”. Surgery for Obesity and Related Diseases (2020): 1-4.
  12. Corral JE., et al. “COVID-19 polymerase chain reaction testing before endoscopy: an economic analysis”. Gastrointestinal Endoscopy (2020): 1-11.
  13. Bilal M., et al. “What constitutes urgent endoscopy? A social media snapshot of gastroenterologists’ views during the COVID-19 pandemic”. Endoscopy International Open 5 (2020): E693-E698.
  14. Sawhney MS., et al. “Triaging advanced GI endoscopy procedures during the COVID-19 pandemic: consensus recommendations using the Delphi method”. Gastrointestinal Endoscopy (2020).
  15. Agyun N., et al. “Endocrine Surgery during the COVID-19 Pandemic: Recommendations from the Turkish Association of Endocrine Surgery”. The Medical Bulletin of Sisli Etfal Hospital 2 (2020): 113-117.
  16. Iddir M., et al. “Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the, COVID-19 Crisis”. Nutrients 12 (2020): 1562.
  17. Akula SM., et al. “Cancer therapy and treatments during COVID-19 era”. Advances in Biological Regulation 77 (2020): 100739.


Citation: Kulvinder Kochar Kaur., et al. “Gastrointestinal and Liver Disorders Encountered during the Covid-19-Pandemic-Strategies to Overcome and Nutritional Input to Boost Immunity". Acta Scientific Microbiology 3.10 (2020): 64-67.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US